These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 37478265)
1. A novel PIBF1-RET gene fusion identified from a stage IA lung adenocarcinoma: A case report. Zhao W; Sun J; Zhu H; Zhao G Medicine (Baltimore); 2023 Jul; 102(29):e34305. PubMed ID: 37478265 [TBL] [Abstract][Full Text] [Related]
2. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671 [TBL] [Abstract][Full Text] [Related]
3. A case of neoadjuvant targeted therapy with pralsetinib for locally advanced lung adenocarcinoma with RET fusion mutation. Chunmao W; Haijie C; Zitong W; Zhi Y J Cardiothorac Surg; 2024 Oct; 19(1):554. PubMed ID: 39354540 [TBL] [Abstract][Full Text] [Related]
4. Pralsetinib treatment for multiple Cao X; Liu X; Wang S; Liu Z; Ren X; Sun D; Deng L J Int Med Res; 2022 Jun; 50(6):3000605221105368. PubMed ID: 35751411 [TBL] [Abstract][Full Text] [Related]
5. Identifification of a novel LDLR-RET Fusion in Lung Adenocarcinoma. Shi G; Luo Y; Yu Z; Wang Y; Zhu B Invest New Drugs; 2022 Aug; 40(4):858-860. PubMed ID: 35524867 [TBL] [Abstract][Full Text] [Related]
6. A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: a case report. Xu X; Wang H; Yu Z; Chen X J Cancer Res Clin Oncol; 2022 Jul; 148(7):1825-1827. PubMed ID: 35364706 [TBL] [Abstract][Full Text] [Related]
7. Identification of a novel KIF13A-RET fusion in lung adenocarcinoma by next-generation sequencing. Zhang X; Li Y; Liu C; Wang W; Li M; Lv D; Sun G; Chen H; Dong X; Miao Z; Yao M; Wang K; Tian H Lung Cancer; 2018 Apr; 118():27-29. PubMed ID: 29571998 [TBL] [Abstract][Full Text] [Related]
8. RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: A case report. Wang Y; Xu Y; Wang X; Sun C; Guo Y; Shao G; Yang Z; Qiu S; Ma K Medicine (Baltimore); 2019 Jan; 98(3):e14120. PubMed ID: 30653139 [TBL] [Abstract][Full Text] [Related]
9. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations. Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228 [TBL] [Abstract][Full Text] [Related]
10. Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene. Qiu Z; Ye B; Wang K; Zhou P; Zhao S; Li W; Tian P Sci Rep; 2020 Jun; 10(1):10387. PubMed ID: 32587276 [TBL] [Abstract][Full Text] [Related]
11. Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET-Rearranged Lung Adenocarcinoma: A Case Report. Gazeu A; Aubert M; Pissaloux D; Lantuejoul S; Pérol M; Ikhlef N; Bouhamama A; Franceschi T; Swalduz A Clin Lung Cancer; 2023 Jan; 24(1):72-75. PubMed ID: 36437214 [TBL] [Abstract][Full Text] [Related]
12. Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report. Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026 [TBL] [Abstract][Full Text] [Related]
13. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Tsuta K; Kohno T; Yoshida A; Shimada Y; Asamura H; Furuta K; Kushima R Br J Cancer; 2014 Mar; 110(6):1571-8. PubMed ID: 24504365 [TBL] [Abstract][Full Text] [Related]
14. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. Wang R; Hu H; Pan Y; Li Y; Ye T; Li C; Luo X; Wang L; Li H; Zhang Y; Li F; Lu Y; Lu Q; Xu J; Garfield D; Shen L; Ji H; Pao W; Sun Y; Chen H J Clin Oncol; 2012 Dec; 30(35):4352-9. PubMed ID: 23150706 [TBL] [Abstract][Full Text] [Related]
15. Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study. Shen T; Pu X; Wang L; Yu Z; Li J; Zhang Y; Liang X; Chen H; Xu C; Song Z; Wang W Clin Lung Cancer; 2020 Sep; 21(5):e349-e354. PubMed ID: 32143967 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer. Sun F; McCoach CE Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651 [TBL] [Abstract][Full Text] [Related]
17. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges. Servetto A; Esposito D; Ferrara R; Signorelli D; Belli S; Napolitano F; Santaniello A; Ciciola P; Formisano L; Bianco R Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188810. PubMed ID: 36202311 [TBL] [Abstract][Full Text] [Related]
18. [Detection of novel driver mutations in liquid biopsy: case report of a RET-positive lung adenocarcinoma treated with pralsetinib.]. Russano M Recenti Prog Med; 2021 Jan; 112(1):5e-9e. PubMed ID: 33512366 [TBL] [Abstract][Full Text] [Related]
19. The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis. Lin C; Wang S; Xie W; Chang J; Gan Y Cancer Biol Ther; 2015; 16(7):1019-28. PubMed ID: 25975578 [TBL] [Abstract][Full Text] [Related]
20. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP). Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]